Sbc Medical Group Holdings Inc (SBC) valuation
Sbc Medical Group P/E ratio history
Sbc Medical Group trades at 11.0 times its earnings over the last twelve months and 10.6 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $4.31 | $0.50 | 8.6 |
| Dec 31, 2024 | $5.56 | $0.48 | 11.6 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Sbc Medical Group valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Sbc Medical GroupSBC | $543M | 11.0 | 10.6 | 3.1 |
| Bright Minds BiosciencesDRUG | $539M | — | — | — |
| Nrc HealthNRC | $537M | 99.3 | 23.0 | 3.8 |
| Aclaris TherapeuticsACRS | $554M | — | — | 67.4 |
| Puma BiotechnologyPBYI | $531M | 20.1 | — | 2.3 |
| Mimedx GroupMDXG | $566M | — | 70.4 | 1.9 |
| Tactile Systems TechnologyTCMD | $520M | 21.5 | 17.6 | 1.5 |
| GeronGERN | $574M | — | — | 2.8 |
| Ironwood PharmaIRWD | $576M | 4.6 | 2.6 | 1.5 |
| Peer median | 20.8 | 20.3 | 2.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: SBC financials · SBC returns
No forecast, no recommendation. This page describes Sbc Medical Group Holdings Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.